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REVIEW
Expert review on coronary calcium
Abstract: While there is no doubt that high risk patients (those with  20% ten year risk of 
future cardiovascular event) need more aggressive preventive therapy, a majority of cardio-
vascular events occur in individuals at intermediate risk (10%–20% ten year risk). Accurate 
risk assessment may be helpful in decreasing cardiovascular events through more appropriate 
targeting of preventive measures. It has been suggested that traditional risk assessment may be 
reﬁ  ned with the selective use of coronary artery calcium (CAC) or other methods of subclini-
cal atherosclerosis measurement. Coronary calciﬁ  cation is a marker of atherosclerosis that can 
be quantiﬁ  ed with the use of cardiac CT and it is proportional to the extent and severity of 
atherosclerotic disease. The published studies demonstrate a high sensitivity of CAC for the 
presence of coronary artery disease but a lower speciﬁ  city for obstructive CAD depending 
on the magnitude of the CAC. Several large clinical trials found clear, incremental predictive 
value of CAC over the Framingham risk score when used in asymptomatic patients. Based on 
multiple observational studies, patients with increased plaque burdens (increased CAC) are 
approximately ten times more likely to suffer a cardiac event over the next 3–5 years. Coronary 
calcium scores have outperformed conventional risk factors, highly sensitive C-reactive protein 
(CRP) and carotid intima media thickness (IMT) as a predictor of cardiovascular events. The 
relevant prognostic information obtained may be useful to initiate or intensify appropriate 
treatment strategies to slow the progression of atherosclerotic vascular disease. Current data 
suggests intermediate risk patients may beneﬁ  t most from further risk stratiﬁ  cation with car-
diac CT, as CAC testing is effective at identifying increased risk and in motivating effective 
behavioral changes. This article reviews information pertaining to the clinical use of CAC for 
assessing coronary atherosclerosis as a useful predictor of coronary artery disease (CAD) in 
certain population of patients.
Keywords: computed tomography, electron beam, prognosis, review, coronary artery calciﬁ  ca-
tion, calcium score, atherosclerosis, multi-detector computed tomography
Introduction
Screening studies to detect occult cancers, such as breast and colon cancer, are recom-
mended in appropriate risk adults to help improve survival in these life-threatening 
conditions (Smith et al 2005). Although atherosclerotic vascular disease accounts for 
more death and disability than all types of cancer, a screening tool to detect subclini-
cal atherosclerosis (such as coronary artery calcium) and target prevention of future 
cardiovascular events is only now starting to be adopted. New guidelines are calling 
for use of a screening test to identify high risk cohorts. The Screening for Heart Attack 
Prevention and Education –SHAPE Guidelines are the most recent national guidelines 
calling for use of atherosclerosis imaging to assist physicians in risk stratiﬁ  cation 
(Figure 1) (Naghavi et al 2006).
In about 50% of individuals, the initial presentation of CAD is a myocardial infarc-
tion (MI) or cardiac death (Kannel and Schatzkin 1985). Conventional ofﬁ  ce-based 
risk screening methods, such as Framingham risk score (FRS) in the United States 
or from the Prospective Cardiovascular Münster (PROCAM) study in Germany, are 
among the most common and widely available for estimating multi-factorial absolute 
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risk in clinical practice; however, these prediction models 
have limitations (Kannel et al 2004). These risk factor 
assessment tools only predict 60%–65% of cardiovascular 
risk, leaving many individuals to have cardiovascular events 
in the absence of traditional risk factors for atherosclerosis 
(Raggi 2002).
Risk stratiﬁ  cation in asymptomatic 
patients
A primary recommendation of the major advisory bodies is 
that all adults should undergo an ofﬁ  ce-based assessment 
as the initial step to identify those at higher risk for a coro-
nary event. The American Heart Association (AHA), the 
American College of Cardiology (ACC), and the National 
Cholesterol Education Program (NCEP) endorse use of the 
risk prediction algorithm from the Framingham Heart Study, 
followed by the Calcium score in certain clinical situations 
(Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults 2001).
The Framingham models create three categories of 10-
year risk for a future cardiovascular event:  10% (low), 
10%–20% (intermediate), and  20% (high). Individuals with 
risk  10% are thought to be at low risk of coronary events 
and current guidelines recommend reassurance without a 
need for further risk stratiﬁ  cation. A sizable group of men 
greater than 45 years of age and women greater than 55 years 
of age are categorized as intermediate risk based on cardio-
vascular risk factors. Patients in this group currently do not 
qualify for the most intensive risk factor interventions, yet 
they may have risk factors that exceed desirable levels. It is 
this group that may beneﬁ  t the most from further risk strati-
ﬁ  cation, as CAC testing is effective at identifying increased 
risk and in motivating effective behavioral changes.
The Framingham score employs data from population-
based studies and does not take into account an individual’s 
actual burden of atherosclerotic disease. Akosah and 
colleagues highlighted the shortcomings of Framingham 
assessment in a study of previously asymptomatic younger 
adults (men  55 and women  65 years of age), who were 
Figure 1 The Algorithm recommended by SHAPE (Screening for Heart Attack and Prevention). Patients with higher calcium scores get increasing therapies, as well as more 
diagnostic workup.Vascular Health and Risk Management 2008:4(2) 317
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hospitalized for their first acute myocardial infarction 
(Akosah et al 2003). Of 222 such patients identiﬁ  ed in a 
three year period, 75% would not have been considered for 
statin therapy according to the NCEP guidelines, suggesting 
missed opportunities for prevention of CHD. Furthermore, 
current population-based risk prediction algorithms appear 
to perform poorly in women (Michos et al 2006).
While a majority of events occur in the intermediate risk 
cohort, treating all these intermediate risk persons will be 
highly cost-inefﬁ  cient. These patients, being asymptomatic 
and not high risk, will have poor long term compliance on 
therapy. In the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT), where hypertensives with three risk factors were 
randomized to a statin or placebo, 93 persons had to be treated 
for 3.3 years to prevent one cardiac event. This trial required 4 
risk factors, so this doesn’t even really address the ‘intermedi-
ate risk population’ (Sever et al 2003). Clearly, this population 
will beneﬁ  t from further risk stratiﬁ  cation, as many deemed 
to be at intermediate risk have no atherosclerosis (low risk) 
and a portion are truly high risk, and would strongly beneﬁ  t 
from pharmacotherapy to reduce their cardiac risk.
The extent of coronary atherosclerosis, rather than the 
severity of stenosis, is the most important predictor of death 
due to acute MI or sudden cardiac death (Schmermund et al 
1997). The quantiﬁ  cation of atherosclerotic burden has 
become vital to proper risk stratiﬁ  cation, especially in the 
intermediate risk population (Mieres et al 2005). Established 
noninvasive methods of evaluating CAD, such as stress 
testing, generally identify only patients with advanced 
atherosclerotic disease leading to a ﬂ  ow-limiting coronary 
stenosis and myocardial ischemia (Greenland and Gaziano 
2003; Rumberger et al 2005). The prognosis of CAD, 
however, is more closely related to atherosclerosis plaque 
burden and stability than the extent of a particular stenosis 
(Stary et al 2003). There is growing interest in quantifying 
and characterizing atherosclerosis in its preclinical, pre-ﬂ  ow 
limiting phase so that appropriate preventive strategies can be 
instituted before an adverse event occurs (Patel et al 2004). 
Cardiac CT, now with both multi-detector row computed 
tomography (MDCT) and EBT, enables the acquisition of 
thin slices of the heart and coronary arteries gated to diastole, 
to minimize coronary motion. Both are sensitive noninvasive 
techniques that can detect and quantify coronary calcium, 
a marker of atherosclerosis (Nasir et al 2003; Greenland 
and Kizilbash 2005). If used in the appropriate population, 
it may assist clinicians to identify individuals who would 
beneﬁ  t from more aggressive primary prevention strategies 
(Budoff et al 2006).
Coronary calcium – basis
and background
The presence of calcium in coronary arteries is pathogno-
monic of atherosclerosis (Budoff et al 2006). The close cor-
relation between the atherosclerotic plaque burden and the 
extent of CAC has been conﬁ  rmed both by histopathology 
and intravascular ultrasound (Mintz et al 1997; Baumgart 
et al 1998). The total CAC score measured represents an 
anatomic measure of overall cardiac plaque burden (Figures 
2–4) (Rumberger et al 1995; Baumgart et al 1997; Mintz et al 
1997; Budoff et al 2006.
Coronary artery calciﬁ  cation
and obstructive disease
Coronary calciﬁ  ed plaque by cardiac CT has a high sen-
sitivity and negative predictive power for obstructive 
CAD but limited speciﬁ  city. CAC can assist the clinician 
in effectively ‘ruling out’ angiographically signiﬁ  cant 
CAD in symptomatic patients. In a study of 1851 patients 
undergoing angiography and CAC (Budoff et al 2002), 
a negative score (no calciﬁ  cation) was highly associated 
with no obstruction on angiography (negative predictive 
power of 98%), and the CAC markedly improved the 
model to predict the presence of obstructive disease. The 
authors suggested that CAC can be used as a ﬁ  lter prior 
to angiography, with negative studies (zero scores) not 
continuing to invasive angiography. Recent guidelines 
state that CAC is “sufﬁ  ciently accurate for predicting the 
presence of angiographic stenosis” and support the use of 
CAC in symptomatic persons (O’Rourke et al 2000; Budoff 
et al 2006). Since calciﬁ  ed plaque may be present in non-
obstructive lesions, the presence of CAC in asymptomatic 
persons does not provide rationale for revascularization, 
but rather risk factor modiﬁ  cation and possible further 
functional assessment. Clinicians must understand a posi-
tive calcium scan indicates atherosclerosis, but most often, 
no signiﬁ  cant stenosis. The absence of coronary calcium 
is most often associated with a normal nuclear test and no 
obstructive disease on angiography.
Miranda et al (2000) demonstrated a relationship 
between CAC and nuclear testing in 233 consecutive 
asymptomatic patients who had CAC and SPECT. No 
patients with a CAC  100 had an abnormal SPECT, 
whereas 4.1 percent with a moderate (101 to 400) CAC and 
15 percent with a CAC  400 had an abnormal SPECT. The 
best CAC cutoff for predicting an abnormal SPECT in this 
study was a score  400 (Miranda et al 2000).Vascular Health and Risk Management 2008:4(2) 318
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A recent study of 1,195 patients who underwent CAC 
measurement with CAC and myocardial perfusion SPECT 
(MPS) assessment demonstrated that CAC was often present 
in the absence of MPS abnormalities (normal nuclear test), and 
that  2% of all patients with CAC  100 had positive MPS 
studies (Berman et al 2004). This is supported by the other 
published reports and is synthesized in a recent appropriateness 
guideline from the American Society of Nuclear Cardiology 
and the American College of Cardiology (Brindis et al 2005). 
The ACC/ASNC appropriateness criteria suggest that a low 
score precludes the need for MPS assessment, and a high score 
would warrant further assessment. These criteria suggest nuclear 
testing may generally be inappropriate in patients with calcium 
scores   100, as the probability of obstruction or abnormal 
scan is very low. A person with an Agatston score  400 may 
beneﬁ  t from functional testing to detect occult ischemia. The 
use of functional testing is paramount to determining the need 
for revascularization, as functionally insigniﬁ  cant lesions do not 
beneﬁ  t from revascularization, and a negative nuclear test carries 
by itself, a low prognostic risk.
Prediction of future cardiac events 
with coronary calcium scores
in symptomatic persons
The ability of CAC to predict future coronary events in symp-
tomatic persons has been demonstrated in multiple studies. 
A multicenter study of 491 patients undergoing coronary 
angiography and EBT scanning found that higher CAC were 
associated with an increased risk of coronary events over the 
next 30 months as compared to patients in the lowest quartile 
of score (odds ratio 10.8, 95% conﬁ  dence interval 1.4 to 85.6) 
(Detrano et al 1996). The atherosclerotic plaque burden, not 
stenosis severity, was a more important marker of disease. 
CAC was a stronger independent predictor of future events 
than a sum of all of the conventional risk factors combined 
(Kennedy et al 1998).
Keelan et al (2001) followed 288 symptomatic persons 
who underwent angiography and calcium scanning for 
a mean of 6.9 years. They found age and CAC were the 
only independent predictors of future hard coronary events 
(RR 3.20, 95% CI 1.17–8.71). Only 1 in 87 patients with 
Figure 2 56-year-old male with family history of heart disease, found to have no coronary calciﬁ  cation. This person was subsequently not treated with statin therapy, after 
being assessed as low risk by CT imaging.Vascular Health and Risk Management 2008:4(2) 319
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CAC   20 experienced a subsequent hard event during 
follow-up. Most important of all, after stepwise multivari-
able analysis, neither angiographic stenosis nor conventional 
coronary risk factors (except age) predicted events.
A study of 192 patients observed for an average of 50 
± 10 months showed that absolute calcium score values were 
strongly related to the occurrence of hard events (p   0.001) 
and all cardiovascular events (p   0.001) (Georgiou et al 
2001). Patients with high scores were 13.2 times more 
likely to suffer a cardiac event than those with low or zero 
scores.
Prediction of events
in asymptomatic persons
using coronary calcium
The extent of CAC has been shown in several studies to 
predict cardiac events in asymptomatic individuals (Table 1). 
Raggi et al reported the occurrence of hard CHD events 
(MI or CHD death) in 632 individuals followed for 
32 months. They found that 70% of patients with hard 
CHD (MI and coronary death) events had a CAC  75th 
percentile, whereas only 25% of patients without an event 
had CAC in this range (p   0.0001) (Raggi et al 2003). For 
the Framingham risk score, the receiving operator char-
acteristic (ROC) curve concordance index (C-index) for 
the estimation of death was 0.67 (95% CI = 0.622–0.722, 
p   0.0001) for women and 0.68 (95% CI = 0.640–0.727, 
p   0.0001) for men. When calciﬁ  cation was added to 
this analysis, a signiﬁ  cant improvement in death estima-
tion was observed for both women (p   0.0001) and 
men (p   0.0001). The C-index increased to 0.75 (95% 
CI = 0.702–0.799) with use of CAC.
In 2003, Shaw and colleagues reported the relationship 
of CAC to all-cause mortality in the largest cohort studied 
to date, consisting of 10,377 asymptomatic individuals (40% 
women), followed for an average of 5 ± 3.5 years. In both 
men and women, CAC was an independent predictor of 
death (p   0.001), and the risk increased proportionally to 
the baseline calcium scores (risk factor adjusted relative risk 
Figure 3 62-year-old sister of patient from Figure 2, found to have moderate calciﬁ  cations and started on statin and aspirin therapy, in addition to lifestyle modiﬁ  cation 
counseling.Vascular Health and Risk Management 2008:4(2) 320
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of 1.6, 1.7, 2.5, and 4 for CAC 11–100, 101–400, 401–1000, 
and greater than 1000 respectively) (Shaw et al 2003). This 
large observational data series shows that coronary calcium 
provides independent incremental information in addition to 
traditional risk factors in the prediction of all-cause mortality. 
Further follow up in another cohort of 25,000 persons dem-
onstrates increasing mortality rates with increasing calcium 
scores (Figure 5).
Wayhs et al (2002) evaluated asymptomatic individuals 
with a very high CAC score (  1000) followed for 17 ± 11 
months. Patients with scores   1000 experienced an annual 
event rate of 25% for hard cardiac events (MI and death). 
Patients with events had signiﬁ  cantly higher CAC scores 
than those without events despite similar age and risk factor 
distribution.
A study demonstrated the risk stratification in 510 
uncomplicated type 2 diabetes in a prospective evaluation 
of measured risk factors, coronary artery calcium and myo-
cardial perfusion scintigraphy (Anand et al 2006). Multivari-
able logistic regression analysis showed that CAC score 
was the only predictor of myocardial perfusion abnormality 
(p   0.001). In the multivariable model, the CAC score and 
extent of myocardial ischemia were the only independent 
predictors of outcome (p   0.0001). ROC analysis demon-
strated that CAC predicted cardiovascular events with the 
best area under the curve (0.92), signiﬁ  cantly better than the 
United Kingdom Prospective Diabetes Study Risk Score 
(0.74) and Framingham Score (0.60, p   0.0001). The rela-
tive risk to predict a cardiovascular event for a CAC score of 
101–400 was 10.1, and increased to 58.1 for scores  1000 
(p   0.0001). The relative risk for ischemic burden was 5.5 
for 1%–5% burden, increasing to 12.3 for an ischemic bur-
den  5% (p   0.0001). No cardiac events occurred in sub-
jects with zero or low calcium scores ( 10) up until 2 years of 
follow-up. CAC and MPS ﬁ  ndings were synergistic for the 
prediction of short-term cardiovascular events. The authors 
concluded that subclinical atherosclerosis, measured by 
CAC imaging, is superior to the established cardiovascular 
risk factors for predicting silent myocardial ischemia and 
short-term outcomes.
Figure 4 Extensive calciﬁ  cations, warranting aggressive medical management for atherosclerosis.Vascular Health and Risk Management 2008:4(2) 321
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Arad et al (2000) in a prospective study following over 
1100 patients for 3.6 years, demonstrated CAC to be the 
strongest predictor of future cardiac events, with patients in 
the highest score category over 20 times more likely to suffer 
a cardiac event (odds ratio: 22.3, CI 5.1–97.4).
The South Bay Heart Watch was the ﬁ  rst study to compare 
the prognostic ability of CAC and highly-sensitive C-reactive 
protein (CRP) (Park et al 2002). This study demonstrated 
that EBT derived CAC were incremental in predicting car-
diac risk, the relative risk (RR) of hard cardiac events (MI 
and death) increased from 1 to 4.9 with increasing calcium 
tertiles (p = 0.005), while highly sensitive CRP failed to add 
independent prognostic value for cardiac events (myocardial 
infarction and death). This study has been followed out to 7 
years, demonstrating consistent predictive abilities of CAC 
for future cardiac events (Greenland et al 2004).
The St. Francis Heart Study, a prospective observa-
tional study of almost 5000 persons, evaluated coronary 
calcium scores, risk factors and C-reactive protein, and 
included these variables in the multivariate model. (Arad, 
Goodman, et al 2005). A calcium score  100 (moderate 
plaque present) predicted all atherosclerotic cardiovascular 
disease events and the sum of non-fatal MI and coronary 
death events with relative risks of 9.5 to 10.7 at 4.3 years, 
as compared to patients with scores  100. This prospective 
study strongly demonstrated the ability to utilize this test 
to rule out patients who don’t need therapy. Persons with 
zero scores had event rates of one per one thousand per-
sons per year, demonstrating a low risk group that may be 
effectively treated with lifestyle changes. Similar to Park 
et al (2002) EBT was predictive of coronary events, while 
highly sensitive CRP was not.
Wong et al (2000) in a study of almost 1000 persons fol-
lowed for three years, demonstrated that the calcium score 
predicted events independently of age, gender, and other car-
diovascular risk factors (RR 8.8 for scores in the top quartile, 
after adjusting for conventional risk factors). The presence of 
CAC and increasing score quartiles were related to the occur-
rence of new MI (p   0.05), revascularization (p   0.001) 
and total cardiovascular events (p   0.001).
Kondos et al (2003) reported a 37-month follow-up on 
5,635 initially asymptomatic low to intermediate risk adults 
(mean age 51 ± 9 years). Patients with scores  170 had a 
relative risk for developing hard cardiac events of 7.2 (95% 
CI, 2.0–26.2), after multivariable analysis was performed 
with adjustment for age and other CAD risk factors. The 
presence of CAC provided incremental prognostic informa-
tion over age and other risk factors.
Figure 5 Ten-year follow up for all cause mortality. Patients with scores  1000 had a 26% mortality rate, multiples higher than patients without coronary calciﬁ  cation.Vascular Health and Risk Management 2008:4(2) 322
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In the Rotterdam Coronary Calciﬁ  cation Study, 2013 
participants (mean age 71 ± 5.7 years) were evaluated. 
(Vliegenthart, Oudkerk, et al 2002). Compared to subjects in 
the lowest calcium score category (0-100), the age-adjusted 
odds ratio for MI in the highest score category was 7.7 (95% 
CI 4.1–14.5) for men and 6.7 (95% CI 2.4–19.1) for women. 
It was also reported that subjects were three times more likely 
to have experienced a stroke with calcium scores  500 (OR 
3.3, 95% CI 1.5–7.2) as compared to subjects in the lowest 
calcium score category ( 100), and adjusting for carotid 
intimal thickness and cardiovascular risk factors did not alter 
the risk estimates (Vliegenthart, Hollander, et al 2002). In 
this ﬁ  rst study reporting the prognostic ability of both IMT 
and CAC, only CAC was predictive. Further studies with 
both modalities are ongoing.
Limitations
Although over 1,000 articles have appeared over the past two 
decades about the use of cardiac CT in coronary calciﬁ  cation 
imaging, a number of questions remain unanswered regard-
ing its application in the clinical setting. There is now direct 
data on the outcome of intervention based on the calcium 
score, the St. Francis Heart Study (Arad, Spadaro, et al 2005). 
Treatment with atorvastatin 20 mg/dl reduced low-density 
lipoprotein cholesterol by 39% to 43% (p   0.0001), and 
triglycerides by 11% to 17% (p = 0.02), while reducing 
clinical endpoints by 30% (6.9% vs. 9.9%, p = 0.08). Event 
rates were related to baseline calcium score and were reduced 
in a subgroup of participants with baseline calcium score 
 400 (8.7% vs. 15.0% [42% reduction], p = 0.046). The 
magnitude of the risk reductions were similar to studies of 
the same cholesterol lowering agent in studies published to 
date in primary prevention cohorts (Sever 2003). Assuming 
a 30% improvement in life-expectancy associated with CAC 
screening, Taylor et al found that identifying patients with 
CAC is cost effective (Taylor et al 2005). The most cost-
effectiveness use of CAC would be use in deciding who does 
not need expensive statin therapy in the short term. Two of 
the largest studies with measured risk factors demonstrate 
a post-test probability of events of approximately 0.1% per 
year for persons without calciﬁ  cation present. Taylor et al 
(2005) prospectively followed 3,000 persons (mean age 43 
years) for 3 years. CHD events occurred in only 2 of 1,263 
participants without CAC (event rate 0.16%; p   0.0001). 
Thus, a negative scan was associated with a 0.05% per year 
risk of events. In the St Francis Heart Study with 4,903 
asymptomatic persons age 50 to 70 years, only 8/1504 (0.5%) 
persons with scores of zero had a coronary event over the 
next 4.3 years; with an annual event rate of only 0.1%. Two 
other prospective studies demonstrated no events in persons 
with scores of zero over 2–3 years of followup (Arad et al 
2000; Becker et al 2005).
Ongoing studies should further clarify populations that 
would beneﬁ  t from CAC scoring. The Multi-Ethnic Study 
of Atherosclerosis (MESA) will assess the long-term out-
come of 6,814 adults aged 45-85 who were felt to be free 
of cardiovascular disease at baseline and underwent cardiac 
CT, as well as other imaging and non-imaging tests (Bild 
et al 2005). This study will shed further light on the role of 
cardiac CT in primary prevention, as well the track calcium 
accumulation in the progression of atherosclerotic disease 
in diverse ethnic groups including African Americans, His-
panics, and Caucasians. In this study, CAC scoring is not 
blinded so resulting changes in treatment initiated by physi-
cians may affect outcomes. The Heinz Nixdorf Recall Study 
(Schmermund et al 2002) is an ongoing study in 4800 men 
and women (47% female) that will assess the natural history 
after calcium scoring, as neither the physician nor the patient 
will be aware of the calcium scores. The results of this study 
should be available in the next year.
Recommendations from 
professional societies
In the spring of 2005, an AHA Scientiﬁ  c Statement regarding 
the evaluation of coronary artery calcium in women stated, 
“Given the evolving literature… current data indicate that 
CAD risk stratiﬁ  cation is possible. Speciﬁ  cally, low CAC 
scores are associated with a low adverse event risk, and high 
CAC scores are associated with a worse event-free survival.” 
This guideline included a recommendation to measure 
atherosclerosis burden using CAC, in clinically selected 
intermediate–CAD risk patients (eg, those with a 10% to 
20% Framingham 10-year risk estimate) to reﬁ  ne clinical 
risk prediction and to select patients for altered targets for 
lipid-lowering therapies (Mieres et al 2005). The European 
Cardiovascular Guidelines state, “The resulting calcium score 
is an important parameter to detect asymptomatic individuals 
at high risk for future CVD events, independent of the tradi-
tional risk factors.” (De Baker 2003). Both the American Col-
lege of Cardiology and American Heart Association (Budoff 
et al 2006) have recently updated their recommendations on 
coronary calcium at this time.
Conclusion
The vast majority of heart attacks (60%–83%) occur at the 
site of a non-obstructive plaque (Giroud et al 1992). Exercise Vascular Health and Risk Management 2008:4(2) 323
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testing or pharmacologic cardiac imaging (nuclear or echo) 
will only diagnose high grade coronary stenoses. They will 
fail to identify a vast number of asymptomatic patients at 
risk because an obstructive coronary plaque (stenosis in the 
artery of  50% severity) is most often NOT the site of the 
cardiovascular event (MI or sudden cardiac death) (Little 
et al 1988). Framingham models miss a signiﬁ  cant portion of 
patients, inappropriately stratiﬁ  ed to intermediate or low risk. 
New scientiﬁ  c statements from the AHA (Budoff et al 2006) 
and SHAPE (Naghavi et al 2006) support the statement from 
the AHA perspective paper (Greenland et al 2001), which 
stated, “…with a prior probability of a coronary event in the 
intermediate range ( 6% in 10 years but  20% in 10 years), 
a calcium score of  100 would yield a post-test probability 
in virtually all such patients greater than 2% per year, that is, 
a level similar to that in secondary prevention, or a ‘coronary 
risk equivalent.’” Therefore, all patients with CAC scores 
 100 should (Figure 4) be considered for statin therapy, 
aspirin and possibly ACE inhibition, given the increased 
cardiovascular risk associated with this level of coronary 
atherosclerosis, concurring with the current NCEP Adult 
Treatment Panel (ATP) III guidelines. This will support the 
conclusions of the Prevention Conference V and the AHA 
report that high coronary calcium scores conﬁ  rm increased 
risk for future cardiac events: “measurement of coronary 
calcium is an option for advanced risk assessment in appro-
priately selected persons. In persons with multiple risk fac-
tors, high coronary calcium scores (eg,  75th percentile for 
age and sex) denote advanced coronary atherosclerosis and 
provide a rationale for intensiﬁ  ed LDL lowering therapy.” 
By identifying high-risk patients, CAC may help select those 
patients who would beneﬁ  t most from additional testing (εγ, 
non-invasive stress imaging) and intensiﬁ  cation of medical 
therapy. Furthermore, the AHA (American Heart Associa-
tion) scientiﬁ  c statement states, “A negative test (score = 
0) makes the presence of atherosclerotic plaque, including 
unstable or vulnerable plaque, highly unlikely, and is con-
sistent with a low risk (0.1% per year) of a cardiovascular 
event in the next 2–5 years”. CAC can be used as an effective 
ﬁ  lter before considering invasive angiography.
Conclusion
It has been shown that the presence of coronary calcium 
is predictive of future coronary events in both asymptom-
atic and symptomatic populations. This technology also 
provides an opportunity to assess the progression of CAD 
non-invasively and monitor the clinical efﬁ  cacy of medical 
therapies by tracking the changing calcium score. As clinical 
decision making regarding the need for medical intervention 
can often be uncertain in asymptomatic individuals with one 
or more conventional risk factors for coronary disease, a 
technology such as CAC will become integral.
From the available data, intermediate risk patients beneﬁ  t 
most from further risk stratiﬁ  cation, as CAC testing is effec-
tive at identifying increased risk and in improving adherence 
to statin therapy (Kalia et al 2006). Integrating evidence 
regarding all available techniques is needed to determine 
the most practical and effective system for assessing cardiac 
risk to optimally target and follow the effect of preventive 
measures.
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